Rewiring Radiation: How FuseRx is Breaking the Four-Week Bottleneck

Rewiring Radiation: How FuseRx is Breaking the Four-Week BottleneckBOONE, N.C. – September 24, 2026 – In the high-stakes economy of cancer care, time is a currency that patients cannot afford to lose, yet the U.S. healthcare system routinely squanders it. For the average radiation oncology patient, the agonizing purgatory between an initial consultation and the first beam-on treatment spans roughly 21 to 29 days. This delay is rarely a failure of medical science; it is a failure of administrative mechanics.Today, Fuse Oncology announced a major expansion of its clinical workflow platform, FuseRx, aiming to dismantle this systemic bottleneck. Originally launched in July as a tool for physicians to digitize consult notes and treatment intent, the platform is now extending its reach to the entire radiation oncology care team. By bringing medical physicists, dosimetrists, radiation therapists, and oncology nurses into a single, unified data environment, the North Carolina-based software company is attempting to rewrite the operational blueprint of cancer clinics nationwide.The expanded multi-role workflow, which incorporates newly licensed treatment-planning technology from the University of Michigan, will be showcased at the American Society for Radiation Oncology (ASTRO) Annual Meeting in Boston. But beyond the trade show floor, the platform’s underlying metrics signal a broader strategic shift in how health systems are leveraging middleware to untangle the complexities of multidisciplinary care.Eliminating the Four-Week WaitTo understand the commercial and clinical value of FuseRx, one must first dissect the friction that defines conventional radiotherapy. The traditional journey from prescription to treatment is a gauntlet of sequential handoffs. A physician’s initial intent must survive an obstacle course of insurance prior authorizations, CT simulations, target contouring, dosimetry planning, and rigorous physics quality assurance. Historically, these discrete steps have been managed in functional silos, tethered together by a fragile web of PDFs, faxes, fragmented electronic health record sticky notes, and hallway conversations. If a physician alters a dose constraint midway through the process, the change often triggers a cascading delay across the entire department.FuseRx attacks this latency through radical workflow parallelization. By structuring the physician’s intent upfront with clinic-configurable templates and automated organ-constraint validations, the software eliminates the dead time between handoffs.The operational prototype for this system was forged at Cone Health Radiation Oncology, a regional network that recently became part of Risant Health under the Kaiser Foundation Hospitals umbrella. Through the deployment of the underlying FuseRx architecture, Cone Health successfully compressed its consult-to-treatment turnaround time to an astonishing 3.4 days. In an industry where palliative rapid-access programs struggle to hit five-day turnarounds, achieving a sub-four-day average across a broad patient population represents a seismic operational advantage."Overwhelmingly, patients we speak with want the same thing: to start treatment within 24 hours," said James Bauler, Chief Executive Officer of Fuse Oncology. "We started FuseRx with the physician because that is where the plan begins, but the real power comes from incorporating the rest of the care team into that same workflow."The Middleware Strategy in a Duopoly MarketFrom a market perspective, Fuse Oncology is navigating a landscape dominated by a deeply entrenched duopoly. The global radiation oncology information system sector is largely controlled by Varian Medical Systems, now a Siemens Healthineers company, with its ARIA platform, and Elekta AB with its MOSAIQ software. Together, these giants control the linear accelerator delivery networks that physically radiate tumors.For years, hospitals have struggled with vendor lock-in, as both Varian and Elekta offer end-to-end proprietary ecosystems. Clinics operating mixed-fleet environments—often the result of regional mergers and acquisitions—face severe integration headaches when trying to standardize clinical pathways across incompatible machines.Rather than attempting a multi-million-dollar replacement of this core infrastructure, FuseRx is positioned as an intelligent middleware layer. It operates above the core systems, pushing and pulling bidirectional intent data seamlessly into both ARIA and MOSAIQ. Independent medical physicists note that this vendor-agnostic approach is critical. By preventing clinicians from having to manually re-enter complex target volumes and dose-fractionation schedules into disparate delivery consoles, the software effectively neutralizes one of the most persistent sources of data-entry errors in modern radiotherapy. This capability allows health systems to scale their operations and acquire new community clinics without being forced to immediately standardize hardware, preserving capital while unifying the standard of care.From Academic Bench to Commercial ScaleThe expansion of FuseRx also highlights a growing trend in digital health: the rapid commercialization of homegrown academic software. While the foundation of FuseRx originated in the community health trenches of Cone Health, its newly expanded capabilities are powered by BluePrint, a custom treatment-planning application licensed from the University of Michigan.Academic medical centers have long compensated for the shortcomings of commercial software by scripting their own internal workarounds. At the University of Michigan, the Physics and Dosimetry divisions engineered BluePrint to serve as an integrated task manager, tracking the patient journey from intent generation through final beam delivery.Through U-M Innovation Partnerships, Fuse Oncology in-licensed this code base, merging the university’s rigorous academic intellectual property with Cone Health’s high-volume operational mechanics. This represents a sophisticated tech transfer strategy, moving beyond traditional pharmaceutical licensing to commercialize software-as-a-service operational algorithms."Standardized technology applications have the potential to modernize radiotherapy care planning and execution across the treatment team," said Martha Matuszak, PhD, FAAPM, FASTRO, Associate Chair and Director of the Physics Division at the University of Michigan's Department of Radiation Oncology. "We are thrilled to be partnering with Fuse and look forward to assessing the workflow and quality gains that can be made with the technology."Tackling the Staffing Crunch and SafetyBeyond speed and interoperability, the expansion of FuseRx speaks directly to the labor crisis gripping the healthcare sector. Radiation oncology departments are currently facing acute shortages of certified medical dosimetrists, specialized nurses, and medical physicists. Asking diminished teams to process higher patient volumes using legacy, high-friction administrative tools is a recipe for clinical burnout and catastrophic misadministrations.The data emerging from the platform's early adopters suggests that automation can decouple patient volume from headcount. During its multi-year prototype phase, Cone Health reported treating 35 percent more patients than the U.S. average while operating with 34 percent fewer full-time equivalents.Crucially, this lean operational model did not compromise clinical integrity. The department ranked in the 98th percentile nationally for safety culture on the Agency for Healthcare Research and Quality Surveys on Patient Safety Culture, alongside a 97.5 percent patient likelihood-to-recommend score.This high safety rating is largely attributed to the software’s programmatic hard stops. Medical physicists frequently cite uncontrolled, undocumented plan modifications as a leading source of treatment errors. FuseRx introduces a centralized, immutable change-request audit trail. If a prescription parameter violates predefined safety rules or clinical pathway boundaries, the system physically halts the pipeline, alerting the assigned dosimetrist and physicist before the flawed data can reach the delivery console.As health systems increasingly transition toward value-based care models—a shift underscored by Cone Health’s integration into Risant Health—the financial imperative to eliminate clinical variation and reduce the total cost of care has never been higher. By replacing disjointed communication silos with a unified, role-based digital environment, technologies like FuseRx are proving that the most effective way to accelerate cancer treatment is not necessarily by building faster radiation machines, but by fundamentally rewiring the human workflows that power them.